ESMO 2024
PULMÓN
LOCALMENTE AVANZADO O METASTÁSICO
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
MET×MET bispecific antibody davutamig (REGN5093) for
MET-altered advanced non-small cell lung cancer (aNSCLC):
Update from a first-in-human (FIH) study(aNSCLC)
1302P
Risk model for overall survival (OS) based on composite
patient-reported outcomes (PROs) in aNSCLC patients
treated with first-line (1L) cemiplimab-based therapy
1853P
ALINA: exploratory biomarker analyses in patients (pts) with
resected ALK+ non-small cell lung cancer (NSCLC) treated
with adjuvant alectinib vs chemotherapy (chemo)
1206MO
Associations of ctDNA clearance (CL) during neoadjuvant Tx
with pathological response and event-free survival (EFS) in
pts with resectable NSCLC (R-NSCLC): Expanded
analyses from AEGEAN
LBA49
CCTG BR.31: A global, double-blind placebo-controlled,
randomized phase III study of adjuvant durvalumab in
completely resected non-small cell lung cancer (NSCLC)
LBA48
Perioperative nivolumab (NIVO) v placebo (PBO) in patients
(pts) with resectable NSCLC: Clinical update from the phase
III CheckMate 77T study
LBA50
ESTADIO TEMPRANO
Regístrate aquí para recibir más contenidos
Registrarse